Literature DB >> 18404539

Change in histone H3 phosphorylation, MAP kinase p38, SIR 2 and p53 expression by resveratrol in preventing streptozotocin induced type I diabetic nephropathy.

Kulbhushan Tikoo1, Karmveer Singh, Dhiraj Kabra, Vikram Sharma, Anil Gaikwad.   

Abstract

Resveratrol has been reported to have a wide variety of biological effects. However, little is known regarding its role on phosphorylation of histone H3, MAP kinase p38, SIR2 and p53 in type I diabetic nephropathy (DN). Hence, the present study was undertaken to examine changes in the above said parameters by resveratrol treatment. Male Sprague-Dawley rats were rendered diabetic using a single dose of streptozotocin (55 mg/kg, i.p.). DN was assessed by measurements of blood urea nitrogen and creatinine levels. Phosphorylation of histone H3, SIR2, p53 and MAP kinase p38 expression were examined by western blotting. This study reports that treatment of resveratrol prevents the decrease in the expression of SIR2 in diabetic kidney. It also prevents increase in p38, p53 expression and dephosphorylation of histone H3 in diabetic kidney. This is the first report which suggests that protection against development of diabetic nephropathy by resveratrol treatment involves change in phosphorylation of histone H3, expression of Sir-2, p53 and p38 in diabetic kidney.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18404539     DOI: 10.1080/10715760801998646

Source DB:  PubMed          Journal:  Free Radic Res        ISSN: 1029-2470


  29 in total

1.  Resveratrol suppresses colitis and colon cancer associated with colitis.

Authors:  Xiangli Cui; Yu Jin; Anne B Hofseth; Edsel Pena; Joshua Habiger; Alexander Chumanevich; Deepak Poudyal; Mitzi Nagarkatti; Prakash S Nagarkatti; Udai P Singh; Lorne J Hofseth
Journal:  Cancer Prev Res (Phila)       Date:  2010-03-23

Review 2.  Interventions against nutrient-sensing pathways represent an emerging new therapeutic approach for diabetic nephropathy.

Authors:  Daisuke Koya; Munehiro Kitada; Shinji Kume; Keizo Kanasaki
Journal:  Clin Exp Nephrol       Date:  2013-11-14       Impact factor: 2.801

3.  In vivo RNA interference models of inducible and reversible Sirt1 knockdown in kidney cells.

Authors:  Peter Y Chuang; Jin Xu; Yan Dai; Fu Jia; Sandeep K Mallipattu; Rabi Yacoub; Leyi Gu; Prem K Premsrirut; John C He
Journal:  Am J Pathol       Date:  2014-07       Impact factor: 4.307

4.  Control of stability of cyclin D1 by quinone reductase 2 in CWR22Rv1 prostate cancer cells.

Authors:  Tze-chen Hsieh; Ching-Jen Yang; Chia-Yi Lin; Yong-Syu Lee; Joseph M Wu
Journal:  Carcinogenesis       Date:  2012-01-19       Impact factor: 4.944

Review 5.  Sirtuin 1: A Target for Kidney Diseases.

Authors:  Lili Kong; Hao Wu; Wenhua Zhou; Manyu Luo; Yi Tan; Lining Miao; Lu Cai
Journal:  Mol Med       Date:  2015-01-12       Impact factor: 6.354

6.  Respected Sir(2): magic target for diabetes.

Authors:  Pratibha V Nerurkar; Vivek R Nerurkar
Journal:  Cellscience       Date:  2008-04-27

7.  Upregulation of microRNA-146a was not accompanied by downregulation of pro-inflammatory markers in diabetic kidney.

Authors:  Mohammad Reza Alipour; Amir Mahdi Khamaneh; Nasibeh Yousefzadeh; Daryoush Mohammad-nejad; Farhad Ghadiri Soufi
Journal:  Mol Biol Rep       Date:  2013-09-21       Impact factor: 2.316

Review 8.  Autophagy in Chronic Kidney Diseases.

Authors:  Na Liu; Yingfeng Shi; Shougang Zhuang
Journal:  Kidney Dis (Basel)       Date:  2016-03-24

9.  Stage-specific quantitative changes in renal and urinary proteome during the progression and development of streptozotocin-induced diabetic nephropathy in rats.

Authors:  Vikram Sharma; Kulbhushan Tikoo
Journal:  Mol Cell Biochem       Date:  2013-11-27       Impact factor: 3.396

10.  Mitigating Effect of Resveratrol on the Structural Changes of Mice Liver and Kidney Induced by Cadmium; A Stereological Study.

Authors:  Ali Rafati; Leila Hoseini; Ali Babai; Ali Noorafshan; Hossein Haghbin; Saied Karbalay-Doust
Journal:  Prev Nutr Food Sci       Date:  2015-12-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.